BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15308738)

  • 1. Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.
    Bernet J; Mullick J; Panse Y; Parab PB; Sahu A
    J Virol; 2004 Sep; 78(17):9446-57. PubMed ID: 15308738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.
    Isaacs SN; Argyropoulos E; Sfyroera G; Mohammad S; Lambris JD
    J Virol; 2003 Aug; 77(15):8256-62. PubMed ID: 12857894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of complement regulatory domains in vaccinia virus complement control protein.
    Mullick J; Bernet J; Panse Y; Hallihosur S; Singh AK; Sahu A
    J Virol; 2005 Oct; 79(19):12382-93. PubMed ID: 16160165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.
    Meseda CA; Kuhn J; Atukorale V; Campbell J; Weir JP
    Clin Vaccine Immunol; 2014 Sep; 21(9):1330-8. PubMed ID: 25030055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation.
    Yadav VN; Pyaram K; Mullick J; Sahu A
    J Virol; 2008 Apr; 82(7):3283-94. PubMed ID: 18216095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of complement activity by vaccinia virus complement-control protein.
    McKenzie R; Kotwal GJ; Moss B; Hammer CH; Frank MM
    J Infect Dis; 1992 Dec; 166(6):1245-50. PubMed ID: 1431243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis.
    Fukui A; Yuasa-Nakagawa T; Murakami Y; Funami K; Kishi N; Matsuda T; Fujita T; Seya T; Nagasawa S
    J Biochem; 2002 Nov; 132(5):719-28. PubMed ID: 12417021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein.
    Ahmad M; Raut S; Pyaram K; Kamble A; Mullick J; Sahu A
    J Immunol; 2010 Nov; 185(10):6128-37. PubMed ID: 20956343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance.
    Smith SA; Sreenivasan R; Krishnasamy G; Judge KW; Murthy KH; Arjunwadkar SJ; Pugh DR; Kotwal GJ
    Biochim Biophys Acta; 2003 Aug; 1650(1-2):30-9. PubMed ID: 12922167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.
    Barilla-LaBarca ML; Liszewski MK; Lambris JD; Hourcade D; Atkinson JP
    J Immunol; 2002 Jun; 168(12):6298-304. PubMed ID: 12055245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation.
    Liszewski MK; Leung MK; Hauhart R; Buller RM; Bertram P; Wang X; Rosengard AM; Kotwal GJ; Atkinson JP
    J Immunol; 2006 Mar; 176(6):3725-34. PubMed ID: 16517741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.
    Iwata K; Seya T; Yanagi Y; Pesando JM; Johnson PM; Okabe M; Ueda S; Ariga H; Nagasawa S
    J Biol Chem; 1995 Jun; 270(25):15148-52. PubMed ID: 7541036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.
    Kumar J; Yadav VN; Phulera S; Kamble A; Gautam AK; Panwar HS; Sahu A
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.
    Ganesh VK; Smith SA; Kotwal GJ; Murthy KH
    Proc Natl Acad Sci U S A; 2004 Jun; 101(24):8924-9. PubMed ID: 15178763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP).
    Rosengard AM; Alonso LC; Korb LC; Baldwin WM; Sanfilippo F; Turka LA; Ahearn JM
    Mol Immunol; 1999 Jul; 36(10):685-97. PubMed ID: 10509819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
    Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
    J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of two amino acids confers C3b binding to the C4b binding site of CR1 (CD35). Analysis based on ligand binding by chimpanzee erythrocyte complement receptor.
    Subramanian VB; Clemenza L; Krych M; Atkinson JP
    J Immunol; 1996 Aug; 157(3):1242-7. PubMed ID: 8757632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in alpha-chain of C4BP that selectively affect its factor I cofactor function.
    Blom AM; Villoutreix BO; Dahlbäck B
    J Biol Chem; 2003 Oct; 278(44):43437-42. PubMed ID: 12893820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.
    Bernet J; Ahmad M; Mullick J; Panse Y; Singh AK; Parab PB; Sahu A
    Vaccine; 2011 Oct; 29(43):7435-43. PubMed ID: 21803094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.